#Israel #Immunotherapy #Compugen #Holon #CGEN

Compugen's Participation in November Investor Conferences

Compugen Ltd., a leading clinical-stage company focused on cancer immunotherapy, is set to present at two major investor conferences in November 2026. The company, known for its pioneering work in computational target discovery powered by artificial intelligence, aims to engage with investors and showcase its innovative pipeline in the field of immuno-oncology.

Upcoming Conferences

1. Stifel 2026 Healthcare Conference
- Date: November 10, 2026
- Location: New York, NY
- Format: Fireside chat and one-on-one meetings
- Fireside Chat Time: 11:20 AM ET

2. Jefferies Global Healthcare Conference
- Date: November 18-19, 2026
- Location: London, UK
- Format: One-on-one meetings

Investors interested in scheduling a meeting with Compugen are urged to contact their representatives at Stifel or Jefferies for more details. Additionally, a live webcast of the fireside chat at the Stifel conference will be available, with a replay accessible afterward through Compugen's Investor Relations page at www.cgen.com.

Company Overview

Compugen specializes in therapeutic discovery and development, using its proprietary platform, Unigen™, to identify new drug targets. The company's mission is to enhance cancer treatment through refined immunotherapies that utilize unique mechanisms of action.

Among its promising candidates, Compugen's immuno-oncology pipeline features:

• - COM701: This potentially first-in-class anti-PVRIG antibody is currently undergoing a clinical trial as a maintenance therapy for relapsed platinum-sensitive ovarian cancer. The trial is dubbed the MAIA-ovarian trial, where its efficacy is being evaluated as a solo agent.
• - Rilvegostomig: A versatile PD-1/TIGIT bispecific antibody derived from the company's previous anti-TIGIT antibody, COM902. This candidate is under evaluation in multiple clinical settings, including several Phase 2 and 3 trials, thanks to collaboration with AstraZeneca, based on an exclusive licensing agreement.
• - GS-0321: Previously known as COM503, this high-affinity antibody interrupts the interaction between IL-18 binding protein and IL-18. It is currently in a Phase 1 clinical trial managed by Compugen after being licensed to Gilead.

Additionally, Compugen is pursuing early-stage research programs aimed at augmenting anti-cancer immunity through various strategies.

Conclusion

Compugen's participation in the upcoming investor conferences marks an essential step in its journey to shine a light on the future of cancer immunotherapy. With an impressive line-up of innovative treatments nearing clinical evaluations, stakeholders will have the opportunity to learn more about the company's transformative approach and significant advancements in the field of oncological therapeutics.

For further inquiries about the conferences or the company’s pipeline, Investors can reach Lindsey Trickett, Compugen’s Head of Investor Relations and Corporate Communications, via email at [email protected] or by phone at +1 (628) 241-0071.